Figure 2.
Kaplan-Meier curves for PFS for all patients treated with crizotinib, n=22 (A), and for all patients treated with 1st line crizotinib, n=11 (B), with median PFS of 8 and 15 months, respectively. PFS, progression-free survival.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.